BRPI0409374A - composto, composição farmacêutica, uso de pelo menos um composto, e, método para o tratamento de um distúrbio médico - Google Patents
composto, composição farmacêutica, uso de pelo menos um composto, e, método para o tratamento de um distúrbio médicoInfo
- Publication number
- BRPI0409374A BRPI0409374A BRPI0409374-7A BRPI0409374A BRPI0409374A BR PI0409374 A BRPI0409374 A BR PI0409374A BR PI0409374 A BRPI0409374 A BR PI0409374A BR PI0409374 A BRPI0409374 A BR PI0409374A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- cycloalkyl
- compound
- haloalkyl
- atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE PELO MENOS UM COMPOSTO, E, MéTODO PARA O TRATAMENTO DE UM DISTúRBIO MéDICO" A invenção refere-se aos compostos N-¢(piperazinil) hetaril! arilsulfonamida de fórmula geral (I) em que Q é um radical heteroaromático de 6 membros bivalente que possui 1 ou 2 átomos de N como membros de anel e que opcionalmente transporta um ou dois substituintes R aque é/são selecionado(s), independentemente um de cada outro, dentre halogênio, CN, NO~ 2~, CO~ 2~R¬ 4¬, COR¬ 5¬, alquila C~ 1~-C~ 4~ e haloalquila C~ 1~-C~ 4~-; Ar é fenila ou um radical heteroaromático de 6 membros que possui 1 ou 2 átomos N como membros de anel e que opcionalmente transporta um ou dois substituintes R¬ b¬, que é/são selecionado(s) dentre halogênio, NO~ 2~, CN, CO~ 2~R¬ 4¬, COR¬ 5¬, C~ 1~-C~ 6~-alquila, alquenila C~ 2~-C~ 6~, alquinila C~ 2~-C~ 6~, cicloalquila C~ 3~-C~ 6~, cicloalquil- C~ 3~-C~ 6~- alquila C~ 1~-C~ 4~ e -haloalquila C~ 1~C~ 4~, sendo também possível que dois radicais R¬ b¬ que são ligados aos átomos C adjacentes de Ar estarem juntos com alquileno C~ 3~-C~ 4~-; R¬ 1¬ é hidrogênio, alquila C~ 1~-C~ 4~, haloalquila C~ 1~-C~ 4~, cicloalquila C~ 3~-C~ 6~, cicloalquil C~ 3~-C~ 6~- alquila C~ 1~-C~ 4~, hidroxialquila C~ 1~-C~ 4~, alcóxi C~ 1~-C~ 4~- alquila C~ 1~-C~ 4~, alquenila C~ 3~-C~ 4~-ou alquinila C~ 3~-C~ 4~-; com os radicais n, R¬ 1¬, R¬ 2¬, R¬ 3¬, e R¬ 4¬ tendo os significados dados nas reivindicações da patente, os N-óxidos e os sais de adição de ácido fisiologicamente tolerados destes compostos e às composições farmacêuticas que compreendem pelo menos um composto N-¢(piperazinil) hetaril! arilsulfonamida como reivindicado em uma das reivindicações 1 a 10 e/ou pelo menos um sal de adição de ácido fisiologicamente tolerado de 1 e/ou um N-óxido de 1, onde apropriado junto com veículos fisiologicamente aceitáveis e/ou substâncias auxiliares para tratar doenças que respondem à influência de antagonistas ou agonistas de receptor de dopamina D~ 3~, em particular para tratar doenças do sistema nervoso central e distúrbios da função renal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/413,233 US20040204422A1 (en) | 2003-04-14 | 2003-04-14 | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
PCT/EP2004/003872 WO2004089905A1 (en) | 2003-04-14 | 2004-04-13 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds with affinity for the dopamine d3 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0409374A true BRPI0409374A (pt) | 2006-04-25 |
Family
ID=33131380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0409374-7A BRPI0409374A (pt) | 2003-04-14 | 2004-04-13 | composto, composição farmacêutica, uso de pelo menos um composto, e, método para o tratamento de um distúrbio médico |
Country Status (17)
Country | Link |
---|---|
US (3) | US20040204422A1 (pt) |
EP (1) | EP1613596B1 (pt) |
JP (1) | JP4864694B2 (pt) |
KR (1) | KR101124911B1 (pt) |
CN (1) | CN1805937B (pt) |
AT (1) | ATE388939T1 (pt) |
AU (1) | AU2004228354B2 (pt) |
BR (1) | BRPI0409374A (pt) |
CA (1) | CA2522319C (pt) |
DE (1) | DE602004012400T2 (pt) |
ES (1) | ES2303065T3 (pt) |
IL (1) | IL171421A (pt) |
MX (1) | MXPA05010986A (pt) |
NZ (1) | NZ543101A (pt) |
PL (1) | PL1613596T3 (pt) |
WO (1) | WO2004089905A1 (pt) |
ZA (1) | ZA200509122B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040204422A1 (en) | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
WO2005011654A2 (en) * | 2003-07-29 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
GB0412072D0 (en) * | 2004-05-28 | 2004-06-30 | Syngenta Participations Ag | Chemical compounds |
US20060173015A1 (en) * | 2004-10-29 | 2006-08-03 | George Chiu | Cyclohexyldiamines as selective alpha 1a/1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
FR2878524B1 (fr) * | 2004-12-01 | 2007-01-19 | Bioprojet Soc Civ Ile | Nouveaux derives d'arylpiperazine |
WO2006058649A1 (en) * | 2004-12-03 | 2006-06-08 | F. Hoffmann-La Roche Ag | 3-substituted pyridine derivatives as h3 antagonists |
CA2590339A1 (en) * | 2004-12-16 | 2006-06-22 | Matthias Heinrich Nettekoven | Piperazinyl pyridine derivatives as anti-obesity agents |
AR060213A1 (es) * | 2006-03-31 | 2008-06-04 | Glaxo Group Ltd | Compuesto de piperazinil - piridinil -bencensulfonamida , su uso para fabricar un medicamento proceso para la preparacion del mismo composicion farmaceutica que lo comprende y proceso para prepararla |
TW200808762A (en) * | 2006-04-19 | 2008-02-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor |
KR20100080500A (ko) * | 2007-10-31 | 2010-07-08 | 애보트 게엠베하 운트 콤파니 카게 | 도파민 d3 수용체의 조절에 반응하는 장애를 치료하기에 적합한 벤젠설폰아미드 화합물 |
JP5701213B2 (ja) | 2008-10-10 | 2015-04-15 | インスティチュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー.エル.エー.チャイナ | 新規なドーパミンd3受容体リガンド、その調製及び使用 |
US9227944B2 (en) | 2008-10-10 | 2016-01-05 | Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China | Dopamine D3 receptor ligands and preparation and medical uses of the same |
TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
EP3821947A1 (en) * | 2019-11-13 | 2021-05-19 | Libra Therapeutics, Inc. | Heterocyclic trpml1 agonists |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4577020A (en) * | 1983-01-25 | 1986-03-18 | The Upjohn Company | Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents |
DE4411225A1 (de) * | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
DE4425145A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung von Thiazol- und Thiadiazolverbindungen |
DE4425146A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
DE4425143A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Substituierte Pyrimidinverbindungen und deren Verwendung |
DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
DE19728996A1 (de) * | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
JP4327915B2 (ja) * | 1998-03-30 | 2009-09-09 | 株式会社デ・ウエスタン・セラピテクス研究所 | スルフォンアミド誘導体 |
AU3927699A (en) * | 1998-04-20 | 1999-11-08 | Basf Aktiengesellschaft | New substituted amides, their production and their use |
DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
CA2386457A1 (en) * | 1999-10-06 | 2001-04-12 | Basf Aktiengesellschaft | Inhibitors of the endothelin signalling pathway and .alpha.v.beta.3 integrin receptor antagonists for combination therapy |
DE10040051A1 (de) * | 2000-08-11 | 2002-02-21 | Basf Ag | Derivate des 4-(Trifluormethyl)-phenols sowie Derivate des 4-(Trifluormethylphenyl)-2-(tetrahydropyranyl)ethers und Verfahren zu ihre Herstellung |
DE10131543A1 (de) | 2001-06-29 | 2003-01-16 | Abbott Lab | Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung |
GB0211005D0 (en) * | 2002-05-15 | 2002-06-26 | Ipwireless Inc | System,transmitter,receiver and method for communication power control |
AU2003290346A1 (en) * | 2002-12-24 | 2004-07-22 | Biofocus Plc | Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors |
DE10304870A1 (de) * | 2003-02-06 | 2004-08-19 | Abbott Gmbh & Co. Kg | Triazolverbindungen und ihre therapeutische Verwendung |
MXPA05008441A (es) * | 2003-02-14 | 2005-10-19 | Wyeth Corp | Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6. |
DE10311065A1 (de) * | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
US20040204422A1 (en) | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
US7320979B2 (en) * | 2003-04-14 | 2008-01-22 | Abbott Gmbh & Co. Kg. | N-[(piperazinyl)hetaryl]arylsulfonamide compounds |
US20050113576A1 (en) * | 2003-08-05 | 2005-05-26 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
DE10358004A1 (de) * | 2003-12-11 | 2005-07-14 | Abbott Gmbh & Co. Kg | Ketolactam-Verbindungen und ihre Verwendung |
DE102004027358A1 (de) * | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
WO2006040182A1 (en) * | 2004-10-14 | 2006-04-20 | Abbott Gmbh & Co. Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
MX2007004357A (es) * | 2004-10-14 | 2007-07-17 | Abbott Gmbh & Co Kg | Compuestos aminoetilaromaticos adecuados para tratar trastornos que responden a la modulacion del receptor de dopamina d3. |
MX2007006598A (es) * | 2004-12-02 | 2007-09-21 | Abbott Gmbh & Co Kg | Compuestos de triazol adecuados para tratar trastornos que responden a la modulacion del receptor de dopamina d3. |
-
2003
- 2003-04-14 US US10/413,233 patent/US20040204422A1/en not_active Abandoned
-
2004
- 2004-04-13 BR BRPI0409374-7A patent/BRPI0409374A/pt active Search and Examination
- 2004-04-13 CA CA2522319A patent/CA2522319C/en not_active Expired - Fee Related
- 2004-04-13 ES ES04726985T patent/ES2303065T3/es not_active Expired - Lifetime
- 2004-04-13 NZ NZ543101A patent/NZ543101A/en not_active IP Right Cessation
- 2004-04-13 PL PL04726985T patent/PL1613596T3/pl unknown
- 2004-04-13 KR KR1020057019566A patent/KR101124911B1/ko not_active IP Right Cessation
- 2004-04-13 WO PCT/EP2004/003872 patent/WO2004089905A1/en active IP Right Grant
- 2004-04-13 US US10/552,842 patent/US20070054918A1/en not_active Abandoned
- 2004-04-13 JP JP2006505100A patent/JP4864694B2/ja not_active Expired - Fee Related
- 2004-04-13 EP EP04726985A patent/EP1613596B1/en not_active Expired - Lifetime
- 2004-04-13 MX MXPA05010986A patent/MXPA05010986A/es active IP Right Grant
- 2004-04-13 CN CN2004800165672A patent/CN1805937B/zh not_active Expired - Fee Related
- 2004-04-13 AT AT04726985T patent/ATE388939T1/de active
- 2004-04-13 AU AU2004228354A patent/AU2004228354B2/en not_active Ceased
- 2004-04-13 DE DE602004012400T patent/DE602004012400T2/de not_active Expired - Lifetime
-
2005
- 2005-10-16 IL IL171421A patent/IL171421A/en not_active IP Right Cessation
- 2005-11-11 ZA ZA2005/09122A patent/ZA200509122B/en unknown
-
2011
- 2011-05-27 US US13/117,269 patent/US8476275B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE602004012400T2 (de) | 2009-04-02 |
NZ543101A (en) | 2009-02-28 |
ZA200509122B (en) | 2007-04-25 |
CN1805937A (zh) | 2006-07-19 |
US20110294817A1 (en) | 2011-12-01 |
PL1613596T3 (pl) | 2008-09-30 |
KR20060005367A (ko) | 2006-01-17 |
US8476275B2 (en) | 2013-07-02 |
CA2522319C (en) | 2013-10-15 |
US20070054918A1 (en) | 2007-03-08 |
JP2006522769A (ja) | 2006-10-05 |
WO2004089905A1 (en) | 2004-10-21 |
JP4864694B2 (ja) | 2012-02-01 |
ATE388939T1 (de) | 2008-03-15 |
MXPA05010986A (es) | 2005-12-15 |
EP1613596B1 (en) | 2008-03-12 |
CN1805937B (zh) | 2012-07-11 |
CA2522319A1 (en) | 2004-10-21 |
IL171421A (en) | 2012-03-29 |
US20040204422A1 (en) | 2004-10-14 |
EP1613596A1 (en) | 2006-01-11 |
AU2004228354A1 (en) | 2004-10-21 |
ES2303065T3 (es) | 2008-08-01 |
DE602004012400D1 (de) | 2008-04-24 |
KR101124911B1 (ko) | 2012-03-27 |
AU2004228354B2 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
EA201891463A1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK) | |
BRPI0409374A (pt) | composto, composição farmacêutica, uso de pelo menos um composto, e, método para o tratamento de um distúrbio médico | |
NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet | |
AR066845A1 (es) | Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer | |
GEP20074148B (en) | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | |
EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
MXPA05010621A (es) | Pirimidinonas sustituidas. | |
TW200517109A (en) | Substituted pyridinones | |
DE602006011434D1 (de) | Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer | |
RU2013138717A (ru) | Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе | |
UA99617C2 (ru) | Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение | |
NO20091590L (no) | Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer | |
DE602005019043D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
ATE390415T1 (de) | Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung | |
ATE543803T1 (de) | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren | |
RU2014119705A (ru) | Пиридин-сульфоксимины в качестве ингибиторов киназы | |
EA200701856A1 (ru) | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении | |
RU2008127260A (ru) | Производные хиназолинона в качестве антагонистов ваниллоидов | |
MY145908A (en) | Amide derivatives bearing a cyclopropylaminocarbonyl substituent useful as cytokine inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |